Article

The Potential of Computational Modeling to Predict Disease Course and Treatment Response in Patients with Relapsing Multiple Sclerosis

2020-01-16

Abstract excerpt

As of today, 20 disease modifying drugs (DMD) have been approved for the treatment of relapsing multiple sclerosis (MS) and, based on their efficacy, they can be grouped into moderate-efficacy DMDs and high-efficacy DMDs. The choice of the drug mostly relies on the judgement and experience of neurologists and the evaluation of therapeutic response can only be obtained by monitoring clinical and magnetic resonance...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 8db605ac-d316-57ae-9bfe-7cff9f5c32cf
DOI: 10.20944/preprints202001.0174.v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

The Potential of Computational Modeling to Predict Disease Course and Treatment Response in Patients with Relapsing Multiple SclerosisDOI 10.20944/preprints202001.0174.v1Read

Therapeutic targeting of oligodendrocytes in an agent-based model of multiple sclerosisSemantic proximity Read

A New Paradigm for the Mathematical Modelling of Multiple SclerosisSemantic proximity Read

Current status and future opportunities in modeling Multiple Sclerosis clinical characteristicsSemantic proximity Read

Agent based modeling of Treg-Teff cross regulation in relapsing-remitting multiple sclerosis.Semantic proximity Read

Characterisation of MS phenotypes across the age span using a novel data set integrating 34 clinical trials (NO.MS cohort): Age is a key contributor to presentation.Semantic proximity Read

Systems-based medicine approaches to understand and treat complex diseases. The example of multiple sclerosis.Semantic proximity Read

Multiscale modeling of mucosal immune responsesSemantic proximity Read

EAE: imperfect but useful models of multiple sclerosisSemantic proximity Read

A Mechanistic, Multiscale Mathematical Model of Immunogenicity for Therapeutic Proteins: Part 2—Model ApplicationsSemantic proximity Read

The 2013 clinical course descriptors for multiple sclerosis: A clarification.Semantic proximity Read

Quantifying MS Progression in the Era of Highly Effective Therapy: Trial Design ImplicationsSemantic proximity Read

The role of age in choosing high-efficacy treatment for multiple sclerosis – an Austrian MS Database studySemantic proximity Read